#12599 Phospho-VEGF Receptor 2 Antibody Sampler Kit
|Phospho-VEGF Receptor 2 (Tyr951) (15D2) Rabbit mAb #4991||20 µl||WB, IHC-P||H, M||230||Rabbit IgG|
|Phospho-VEGF Receptor 2 (Tyr996) Antibody #2474||20 µl||WB||H, M||230||Rabbit|
|Phospho-VEGF Receptor 2 (Tyr1059) (D5A6) Rabbit mAb #3817||20 µl||WB||H, M||R||230||Rabbit IgG|
|Phospho-VEGF Receptor 2 (Tyr1175) (D5B11) Rabbit mAb #3770||20 µl||WB, IP||H, M||230||Rabbit IgG|
|VEGF Receptor 2 (D5B1) Rabbit mAb #9698||20 µl||WB, IP, IHC-P, IF-F, F||H, M, R||210, 230||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
†Species predicted to react based on 100% sequence homology.
Applications Key: W=Western Blotting, IHC-P=Immunohistochemistry (Paraffin), IP=Immunoprecipitation, IF-F=Immunofluorescence (Frozen), F=Flow Cytometry
Reactivity Key: H=Human, M=Mouse, R=Rat
Western blot analysis of extracts from CKR/PAE cells expressing chimeric receptors containing human CSF-1 extracellular binding domain/mouse VEGF receptor 2 intracellular domains (Rahimi, N. et al. (2000) J. Biol. Chem. 275, 16986-16992), using Phospho-VEGF Receptor 2 (Tyr996) Antibody (upper) or VEGF receptor 2 antibody (lower).
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of recombinant human GST-VEGF Receptor 2 (Val789-Val1356), untreated or λ phosphatase-treated, using Phospho-VEGF Receptor 2 (Tyr951) (15D2) Rabbit mAb (upper) and VEGF Receptor 2 Antibody # 2472 (lower).
Western blot analysis of extracts from HUVEC, untreated or stimulated with VEGF #9943, using Phospho-VEGF Receptor 2 (Tyr1175) (D5B11) Rabbit mAb (upper) and VEGF Receptor 2 (55B11) Rabbit mAb (lower) #2479.
Western blot analysis of PAE/CKR cells, untreated or stimulated with CSF-1, using Phospho-VEGF Receptor 2 (Tyr1059) (D5A6) Rabbit mAb (upper) and VEGF Receptor 2 (55B11) Rabbit mAb #2479 (lower). PAE/CKR cells express a chimeric receptor made up of human CSF-1 receptor extracellular domain and mouse VEGF receptor 2 transmembrane and intracellular domains.
Western blot analysis of extracts from HUVE cells, HeLa cells and mouse heart using VEGF Receptor 2 (D5B1) Rabbit mAb for VEGFR2 expression (upper) and β-Actin (D6A8) Rabbit mAb (#8457) for loading control. (The 80 kDa bands represent partial degradation product).
Phospho-VEGF Receptor 2 (Tyr951) (15D2) Rabbit mAb specifically binds to phosphorylated VEGFR2, but not other phosphorylated tyrosine kinases. Western blot analysis of extracts from cells expressing different activated tyrosine kinase proteins, using Phospho-VEGF Receptor-2 (Tyr951) (15D2) Rabbit mAb (upper) or Phospho-Tyrosine Mouse mAb (P-Tyr-100) #9411 (lower). CKR/PAE cells (lanes 13 and 14) express chimeric receptors containing human CSF-1 extracellular binding domain/mouse VEGF receptor-2 intracellular domain (5). CSF-1 stimulates phosphorylation of Tyr951 of intracellular VEGF receptor-2 domain (lane 13) , which was specifically detected by Phospho-VEGF Receptor-2 (Tyr951) (15D2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human angiosarcoma using VEGF Receptor 2 (D5B1) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded HUVEC cells, untreated (left) or VEGF-treated (right), using Phospho-VEGF Receptor-2 (Tyr951) (15D2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded mouse liver using VEGF Receptor 2 (D5B1) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded HCC827 xenograft using VEGFR2 (D5B1) Rabbit mAb.
Flow cytometric analysis of HeLa cells (blue) and HUVE cells (green) using VEGF Receptor 2 (D5B1) Rabbit mAb.
Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, GRB2, PI3 kinase, NCK, and the protein tyrosine phosphatases SHP-1 and SHP-2 (3). Phosphorylation at Tyr1212 provides a docking site for GRB2 binding and phospho-Tyr1175 binds the p85 subunit of PI3 kinase and PLCγ, as well as Shb (1,4,5). Signaling from VEGFR2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and sprouting, as well as survival of cultured endothelial cells in vitro and angiogenesis in vivo (6-8).
- Meyer, M. et al. (1999) EMBO J 18, 363-74.
- Dougher-Vermazen, M. et al. (1994) Biochem Biophys Res Commun 205, 728-38.
- Kroll, J. and Waltenberger, J. (1997) J Biol Chem 272, 32521-7.
- Takahashi, T. et al. (2001) EMBO J 20, 2768-78.
- Holmqvist, K. et al. (2004) J Biol Chem 279, 22267-75.
- Karkkainen, M.J. and Petrova, T.V. (2000) Oncogene 19, 5598-605.
- Rahimi, N. et al. (2000) J Biol Chem 275, 16986-92.
- Claesson-Welsh, L. (2003) Biochem Soc Trans 31, 20-4.
Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at firstname.lastname@example.org.
Tween is a registered trademark of ICI Americas, Inc.
DRAQ5 is a registered trademark of Biostatus Limited.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.